Trial Profile

INtravesical Phase 1/1b Study of STING Agonist E7766 in NMIBC Including Subjects Unresponsive to BCG Therapy, INPUT-102

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I

Latest Information Update: 16 Dec 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs E 7766 (Primary)
Indications Bladder cancer; Carcinoma
Focus Adverse reactions
Acronyms INPUT-102
Sponsors Eisai Inc

Most Recent Events

10 Dec 2020 Status changed from recruiting to withdrawn prior to enrolment.
28 Jul 2020 Planned number of patients changed from 120 to 110.
12 May 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com